Part 3: Risk-based Quality Management Video (RBQM) Series
ICH Q9 (1) focuses on Quality Risk Management. Revisions may influence how we apply and perform risk management in clinical trials. In part three of our RBQM video series, Amy Kissam-Sands and Tim Audin, Senior Director, Global Biometrics Group Lead talk with Taren Grom, Editor, PharmaVOICE about the specific areas they expect ICH Q9 (1) to focus on.
Related Insights
Article
Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct
Sep 14, 2021
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Article
Decentralized trial tools and technologies are here to stay: A regulatory perspective
Jul 23, 2021
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Playbook
The upward trend of FSP outsourcing
Sep 29, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Related Insights
Article
Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct
Sep 14, 2021
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Article
Decentralized trial tools and technologies are here to stay: A regulatory perspective
Jul 23, 2021
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Playbook
The upward trend of FSP outsourcing
Sep 29, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022